November 5, 2013: Darlene Solomon of Agilent Technologies speaks to the "disruptive nature" of synthetic biology technologies from an industrial standpoint. She notes how decades of electronically-focused innovation has dovetailed with biology transitioning from qualitative to quantitative approaches has synthetic biology an emergent 21st century technology. Part of "Tooling the U.S. Bioeconomy: Synthetic Biology" briefing held by ACS Science & the Congress Project on Capitol Hill. #acsscicon

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…